Moolec Science SA Ordinary Shares - Asset Resilience Ratio
Moolec Science SA Ordinary Shares (MLEC) has an Asset Resilience Ratio of 1.54% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Moolec Science SA Ordinary Shares's Asset Resilience Ratio has changed over time. Check Moolec Science SA Ordinary Shares (MLEC) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Moolec Science SA Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Moolec Science SA Ordinary Shares.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.67 Million | 1.54% |
| Total Liquid Assets | $14.67 Million | 1.54% |
Asset Resilience Insights
- Limited Liquidity: Moolec Science SA Ordinary Shares maintains only 1.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Moolec Science SA Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Moolec Science SA Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Moolec Science SA Ordinary Shares (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Moolec Science SA Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 4.03% | $8.25 Million | $204.71 Million | -38.13pp |
| 2024-06-30 | 42.16% | $14.67 Million | $34.79 Million | +40.89pp |
| 2023-06-30 | 1.27% | $306.03K | $24.05 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $5.69 Million | -- |
About Moolec Science SA Ordinary Shares
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans… Read more